Piper Sandler initiated coverage of Merus (MRUS) with an Overweight rating and $84 price target The firm views the company’s EGFRxLGR5 bispecific, petosemtamab, as “significantly de-risked ...

Merus shares rise after the FDA grants Breakthrough Therapy designation for petosemtamab in combination with pembrolizumab for head. Investor optimism grows as the designation accelerates ...

Merus (NASDAQ:MRUS – Get Free Report) saw a large drop in short interest in the month of February.As of February 15th, there was short interest totalling 6,640,000 shares, a drop of 13.5% from ...

Merus has a 12 month low of $37.77 and a 12 month high of $61.61. The firm has a market capitalization of $2.75 billion, a PE ratio of -10.18 and a beta of 1.11. Hedge Funds Weigh In On Merus ...